Springhill Fund Asset Management (HK) Co Ltd
Follow13F filer, CIK 1911270, HONG KONG, Hong Kong
Springhill Fund Asset Management (HK) Co Ltd reported $0 across 1 holding for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-13.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001911270-25-000005
- Period
- 2025-06-30
- Reported value
- $0
- Holdings
- 1
- Top 10 weight
- New
- 1
- Sold out
- 19
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| VERONA PHARMA PLCexited | -63,499 | -$4.03M |
| SMMTexited | -124,307 | -$2.4M |
| JANXexited | -78,500 | -$2.12M |
| REGNexited | -2,600 | -$1.65M |
| NBIXexited | -13,612 | -$1.51M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2025
Share positions as resolved from 13F-HR 0001911270-25-000005, largest first. % of portfolio is the value over $0, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| 00 | 0 | $0 | new | Value filed as zero, left out of ratios.Amount filed as zero, left out of ratios. |
Sold out in Q2 2025
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| VERONA PHARMA PLCVERONA PHARMA PLC | 63,499 | $4.03M | shares |
| SMMTSUMMIT THERAPEUTICS INC | 124,307 | $2.4M | shares |
| JANXJANUX THERAPEUTICS INC | 78,500 | $2.12M | shares |
| REGNREGENERON PHARMACEUTICALS | 2,600 | $1.65M | shares |
| NBIXNEUROCRINE BIOSCIENCES INC | 13,612 | $1.51M | shares |
| INSMINSMED INC | 19,192 | $1.46M | shares |
| SLNOSOLENO THERAPEUTICS INC | 19,858 | $1.42M | shares |
| JAZZJAZZ PHARMACEUTICALS PLC | 9,853 | $1.22M | shares |
| AKROAKERO THERAPEUTICS INC | 19,925 | $807K | shares |
| ARGXARGENX SE | 1,146 | $678K | shares |
| LLYELI LILLY & CO | 816 | $674K | shares |
| PTGXPROTAGONIST THERAPEUTICS INC | 12,859 | $622K | shares |
| TGTXTG THERAPEUTICS INC | 13,500 | $532K | shares |
| TARSTARSUS PHARMACEUTICALS INC | 7,076 | $363K | shares |
| ASNDASCENDIS PHARMA A/S | 2,173 | $339K | shares |
| RYTMRHYTHM PHARMACEUTICALS INC | 6,277 | $332K | shares |
| BNTXBIONTECH SE | 3,000 | $273K | shares |
| SPRINGWORKS THERAPEUTICS INCSPRINGWORKS THERAPEUTICS INC | 5,897 | $260K | shares |
| COGTCOGENT BIOSCIENCES INC | 29,491 | $177K | shares |
How Q2 2025 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001911270-25-000005 | base | 2025-08-13 | acceptance time not in the bulk data set |